Cover

Hepatitis C in Renal Disease, Hemodialysis and Transplantation

Editor(s): Morales J.M. (Madrid) 
Table of Contents
Vol. 176, 2012
Section title: Paper
Morales JM (ed): Hepatitis C in Renal Disease, Hemodialysis and Transplantation. Contrib Nephrol. Basel, Karger, 2012, vol 176, pp 87–96
(DOI:10.1159/000333775)

Treatment of Hepatitis C Virus Infection after Kidney Transplantation

Rostaing L. · Weclawiak H. · Izopet J. · Kamar N.
aDepartment of Nephrology, Dialysis, and Organ Transplantation, CHU Rangueil, Toulouse University Hospital, bLaboratory of Virology, and cINSERM U563, IFR 30, Toulouse, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The prevalence of chronic hepatitis C virus (HCV) infection after kidney transplantation (KT) varies a lot from one country to another. In the setting of (powerful) immunosuppression, HCV replication can sharply increase, thereby leading to potential severe HCV-related liver damage such cirrhosis or fibrosing cholestatic hepatitis. In the setting of KT, α-interferon (α-IFN) therapy alone has been associated with a very low sustained virological response (SVR), and a poor tolerance, particularly with regard to the kidney allograft, i.e. it induces acute rejection. The combined use of α-IFN plus ribavirin leads to a greater rate of SVR, but randomized clinical trials are missing in order to evaluate its safety with respect to the allograft function. Ribavirin monotherapy, or ribavirin plus amantadine therapy are not able to induce SVR; ribavirin may have an effect upon HCV-related proteinuria. Finally, it seems advisable to try and eradicate HCV infection prior to KT, i.e. while the patient is on dialysis therapy. After KT, α-IFN plus ribavirin therapy could be attempted only in those patients developing rapid cirrhosis or in those developing fibrosing cholestatic hepatitis or in those having de novo cryoglobulinemic glomerulonephritis within the allograft.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Kamar N Izopet J Alric L Guilbeau-Frugier C Rostaing L: Hepatitis C virus-related kidney disease: an overview. Clin Nephrol 2008; 69: 149-160
  2. Fabrizi F Dixit V Martin P Messa P: Combined antiviral therapy of hepatitis C virus in dialysis patients: metaanalysis of clinical trials. J Viral Hepat 2011; 18: e263-e269
  3. Cruzado JM Casanovas-Taltavull T Torras J Baliellas C Gil-Vernet S Grinyó JM: Pretransplant interferon prevents hepatitis C virus-associated glomerulonephritis in renal allografts by HCV-RNA clearance. Am J Transplant 2003; 3: 357-360
  4. Kamar N Toupance O Buchler M: Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092-2098
  5. Legendre C Garrigue V Le Bihan C: Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients. Transplantation 1998; 65: 667-670
  6. Hanafusa T Ichikawa Y Kishikawa H: Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 1998; 66: 471-476
  7. Mathurin P Mouquet C Poynard T: Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257
  8. Roth D Zucker K Cirocco R: A prospective study of hepatitis C virus infection in renal allograft recipients. Transplantation 1996; 61: 886
  9. Zylberberg H Nalpas B Carnot F: Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002; 17: 129
  10. Alric L Di-Martino V Selves J: Longterm impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology 2002; 123: 1494
  11. Kamar N Rostaing L Selves J: Natural history of hepatitis C virus-related liver fibrosis after renal transplantation. Am J Transplant 2005; 5: 1704
  12. Tang IY Walzer N Aggarwal N: Management of the kidney transplant patient with chronic hepatitis C infection. Int J Nephrol 2011; 2011: 245823
  13. Rostaing L Izopet J Baron E: Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995; 59: 1426
  14. Thervet E Pol S Legendre C: Low-dose recombinant leukocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 1994; 58: 625
  15. Magnone M Holley JL Shapiro R: Interferon-alpha-induced acute renal allograft rejection. Transplantation 1995; 59: 1068
  16. Rostaing L Modesto A Baron E: Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74: 512
  17. Baid S Tolkoff-Rubin N Saidman S: Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 74
  18. Kim E Ko HH Yoshida EM: Treatment issues surrounding hepatitis C in renal transplantation: a review. Ann Hepatol 2011; 10: 5
  19. Fabrizi F Lunghi G Dixit V Martin P: Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients. Aliment Pharmacol Ther 2006; 24: 1413
  20. Pageaux GP Hilleret MN Garrigues V: Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transpl Int 2009; 22: 562
  21. Sharma RK Bansal SB Gupta A: Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin Transplant 2006; 20: 677
  22. Shu KH Lan JL Wu MJ: Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients. 2004; 77: 1894
  23. Schmitz V Kiessling A Bahra M: Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant 2007; 12: 22
  24. Kamar N Sandres-Saune K Selves J: Long-term ribavirin therapy in hepatitis C virus-positive renal transplant patients: effects on renal function and liver histology. Am J Kidney Dis 2003; 42: 184
  25. Kamar N Boulestin A Selves J: Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. J Med Virol 2005; 76: 61
  26. Smith JP: Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997; 42: 1681
  27. Brillanti S Foli M Di Tomaso M: Pilot study of triple antiviral therapy for chronic hepatitis C in interferon alpha non-responders. Ital J Gastroenterol Hepatol 1999; 31: 130
  28. van Soest H van der Schaar PJ Koek GH: No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Dig Liver Dis 2010; 42: 496
  29. Kamar N Rostaing L Sandres-Saune K: Amantadine therapy in renal transplant patients with hepatitis C virus infection. J Clin Virol 2004; 30: 110
  30. Calanca LN Fehr T Jochum W: Combination therapy with ribavirin and amantadine in renal transplant patients with chronic hepatitis C virus infection is not superior to ribavirin alone. J Clin Virol 2007; 39: 54
  31. Roth D Gaynor JJ Reddy KR: Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 2011; 22: 1152
  32. Muñoz De Bustillo E Ibarrola C Colina F: Fibrosing cholestatic hepatitis in hepatitis C virus-infected renal transplant recipients. J Am Soc Nephrol 1998; 9: 1109
  33. Delladetsima JK Boletis JN Makris F: Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transpl Surg 1999; 5: 294
  34. Toth CM Pascual M Chung RT: Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998; 66: 1254
  35. Basse G Ribes D Kamar N: Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients. Transplant Proc 2006; 38: 2308


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00